Skip to main content
. 2022 Aug;23(8):2755–2761. doi: 10.31557/APJCP.2022.23.8.2755

Table 3.

The Impact of Clarithromycin and Metronidazole Resistance on the Evolution of Gastric Lesions

Histologic lesions Clarithromycin-resistance (%) Clarithromycin-
suceptibility (%)
Metronidazole-resistance (%) Metronidazole-
suceptibility (%)
Chronic gastritis 8 (13,3) 52 (86.7) 67 (62) 41 (38)
Precancerous lesions 6 (16,7) 30 (83.3) 49 (63,6) 28 (36.4)
P-value 0.76 0.87